Tag: Eli Lilly

Tirzepatide’s debut as the first dual GIP and GLP-1 receptor agonist for obesity in China strengthens Eli Lilly’s presence

New Phase IIa results reveal significant weight loss, positioning VK2735 as a potential market leader amid increasing competition

Both Lilly and Novo are projected to experience ongoing market capitalization growth, aligned with the expanding prospects of Lilly's Mounjaro and Novo's Wegovy and Ozempic

The Elecsys Amyloid Plasma Panel has demonstrated clinical performance and is currently undergoing additional investigation to ensure clinical validation

Post approval from the Drugs Controller General of India, the drug will be available for treatment of adults with moderate-to-severe plaque psoriasis

Vineet will take over from Luca Visini who served as Managing Director of the company in India from February 2018 to December 2021

Cipla will leverage its capabilities and robust distribution strengths to engage healthcare professionals and expand access to these treatments for patients who need them...................

Luca Visini, Managing Director, Eli Lilly & Company India shares his views on a variety of questions related to the company's operations in an exclusive interaction with BioVoice....................

Mentioned Luca Visini, Managing Director, Eli Lilly & Company India in an exclusive interaction with BioVoice where he outlined the goals of his company driven by innovation including pursual of new drug development and working towards medicines reaching people at large through different channels.....................

The latest failure of three anti-obesity drugs to provide the anticipated results could lead to the companies taking a cautious approach while investing to develop further drugs in the area.............